Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis

Stroke. 2012 Dec;43(12):3395-8. doi: 10.1161/STROKEAHA.112.670687. Epub 2012 Nov 8.

Abstract

Background and purpose: Earlier tissue-type plasminogen activator (tPA) treatment for acute ischemic stroke increases efficacy, prompting national efforts to reduce door-to-needle times. We used lean process improvement methodology to develop a streamlined intravenous tPA protocol.

Methods: In early 2011, a multidisciplinary team analyzed the steps required to treat patients with acute ischemic stroke with intravenous tPA using value stream analysis (VSA). We directly compared the tPA-treated patients in the "pre-VSA" epoch with the "post-VSA" epoch with regard to baseline characteristics, protocol metrics, and clinical outcomes.

Results: The VSA revealed several tPA protocol inefficiencies: routing of patients to room, then to CT, then back to the room; serial processing of workflow; and delays in waiting for laboratory results. On March 1, 2011, a new protocol incorporated changes to minimize delays: routing patients directly to head CT before the patient room, using parallel process workflow, and implementing point-of-care laboratories. In the pre and post-VSA epochs, 132 and 87 patients were treated with intravenous tPA, respectively. Compared with pre-VSA, door-to-needle times and percent of patients treated ≤60 minutes from hospital arrival were improved in the post-VSA epoch: 60 minutes versus 39 minutes (P<0.0001) and 52% versus 78% (P<0.0001), respectively, with no change in symptomatic hemorrhage rate.

Conclusions: Lean process improvement methodology can expedite time-dependent stroke care without compromising safety.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Brain Ischemia / drug therapy*
  • Efficiency, Organizational
  • Emergency Medical Services / organization & administration*
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Industry / organization & administration
  • Male
  • Middle Aged
  • Models, Organizational*
  • Patient Care Team / organization & administration
  • Program Evaluation
  • Registries / statistics & numerical data
  • Stroke / drug therapy*
  • Time-to-Treatment / organization & administration*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents